CALML3

Across TCGA pan-cancer cohorts, CALML3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CALML3 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CALML3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CALML3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, LSCC, and UCEC are the cancer types where CALML3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.883	0.524	<.001	39	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.740	.003	8	view →
UCEC	DFS	Median	All	0.936	1.000	.023	6	view →
HNSC	OS	Tertile	III,IV	1.000	0.347	.027	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CALML3–CCRCC (DFS)

Open the CCRCC breakdown →